Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 11, 2012 - Issue 3
Submit an article Journal homepage
626
Views
12
CrossRef citations to date
0
Altmetric
Reviews

Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use

Constantin A DasanuSt. Francis Hospital and Medical Center, Department of Hematology-Oncology, Medical Oncology and Blood Disorders, LLP, Gothic Park, 43 Woodland Street, Suite G-80, Hartford, CT 06105, USA+1 347 679 9455; [email protected]
, MD PhD,
Premkumar PadmanabhanUniversity of Connecticut Medical Center, Department of Internal Medicine, Farmington, CT, USA
, MD,
Bernard A. Clark 3rdSt. Francis Hospital and Medical Center, Department of Cardiovascular Medicine, Hartford, CT, USA
, MD &
Christine DoSt. Francis Hospital and Medical Center, Department of Pharmacy, Hartford, CT, USA
, PharmD
Pages 445-457 | Published online: 02 Apr 2012

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Georgia Pitsiou, Paul Zarogoulidis, Dimitris Petridis, Ioannis Kioumis, Sofia Lampaki, John Organtzis, Konstantinos Porpodis, Antonis Papaiwannou, Theodora Tsiouda, Wolfgang Hohenforst-Schmidt, Stylianos Kakolyris, Konstantinos Syrigos, Haidong Huang, Qiang Li, J Francis Turner & Konstantinos Zarogoulidis. (2014) Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment. Drug Design, Development and Therapy 8, pages 1753-1763.
Read now

Articles from other publishers (11)

Zahra Nekoukar, Minoo Moghimi & Ebrahim Salehifar. (2021) A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities. BLOOD RESEARCH 56:4, pages 229-242.
Crossref
Tongtong Yang, Jie Gu, Chong Du, Tiankai Shan, Tianwen Wei, Yafei Li & Liansheng Wang. (2021) Adverse Cerebral Cardiovascular Events Associated With Checkpoint Kinase 1 Inhibitors: A Systemic Review. Journal of Cardiovascular Pharmacology 77:5, pages 549-556.
Crossref
Gerson A. Valencia & Usha Krishnan. (2017) Idiopathic Pulmonary Arterial Hypertension in Children: A Review. Pulmonary Therapy 3:1, pages 67-92.
Crossref
Xiao-Ping Gao, Feng Feng, Xiao-Qi Zhang, Xiao-Xin Liu, Yu-Bin Wang, Jin-Xiong She, Zhi-Heng He & Ming-Fang He. (2014) Toxicity Assessment of 7 Anticancer Compounds in Zebrafish. International Journal of Toxicology 33:2, pages 98-105.
Crossref
Charlotte E. Allen, Amanda J. Welford, Thomas P. Matthews, John J. Caldwell & Ian Collins. (2014) Fragment growing to retain or alter the selectivity of anchored kinase hinge-binding fragments. Med. Chem. Commun. 5:2, pages 180-185.
Crossref
Paul Workman & Ian Collins. 2014. Cancer Drug Design and Discovery. Cancer Drug Design and Discovery 3 53 .
L. Rhoda Molife, Sarah M. Rudman, Salma Alam, Daniel S.-W. Tan, Hartmut Kristeleit, Gary Middleton, David Propper, Liz Bent, Peter Stopfer, Martina Uttenreuther-Fischer, Gudrun Wallenstein, Johann de Bono & James Spicer. (2013) Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemotherapy and Pharmacology 72:6, pages 1213-1222.
Crossref
David A. Scott, Les A. Dakin, Kevin Daly, David J. Del Valle, R. Bruce Diebold, Lisa Drew, Jayachandran Ezhuthachan, Thomas W. Gero, Claude A. Ogoe, Charles A. Omer, Sean P. Redmond, Galina Repik, Kumar Thakur, Qing Ye & Xiaolan Zheng. (2013) Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507. Bioorganic & Medicinal Chemistry Letters 23:16, pages 4591-4596.
Crossref
Rashmi R. Shah, Joel Morganroth & Devron R. Shah. (2013) Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval). Drug Safety 36:5, pages 295-316.
Crossref
Hind Lal, Kyle L. Kolaja & Thomas Force. (2013) Cancer Genetics and the Cardiotoxicity of the Therapeutics. Journal of the American College of Cardiology 61:3, pages 267-274.
Crossref
Constantin A Dasanu. (2012) Length of adjuvant imatinib therapy in GIST: Weighing benefits, side effects and costs. Journal of Oncology Pharmacy Practice 18:3, pages 379-380.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.